Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
54
SBHMY Quote, Financials, Valuation and Earnings
Last price:
$18.22
Seasonality move
:
-3.63%
Day range:
$18.22 - $18.22
52-week range:
$7.15 - $20.16
Dividend yield:
1.26%
P/E ratio:
31.84x
P/S ratio:
3.87x
P/B ratio:
4.29x
Volume:
1
Avg. volume:
25
1-year change:
118.6%
Market cap:
$16.3B
Revenue:
$4B
EPS (TTM):
$0.60
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Sino Biopharmaceutical Ltd. has -- downside to fair value with a price target of -- per share.
SBHMY vs. S&P 500
-
Over the past 5 trading days, Sino Biopharmaceutical Ltd. has underperformed the S&P 500 by -0.1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sino Biopharmaceutical Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sino Biopharmaceutical Ltd. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Sino Biopharmaceutical Ltd. reported revenues of --.
Earnings Growth
-
Sino Biopharmaceutical Ltd. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Sino Biopharmaceutical Ltd. reported earnings per share of --.
Enterprise value:
17.8B
EV / Invested capital:
--
Price / LTM sales:
3.87x
EV / EBIT:
20.21x
EV / Revenue:
4.21x
PEG ratio (5yr expected):
0.33x
EV / Free cash flow:
16.18x
Price / Operating cash flow:
14.88x
Enterprise value / EBITDA:
16.65x
Gross Profit (TTM):
$3.5B
Return On Assets:
5.38%
Net Income Margin (TTM):
22.11%
Return On Equity:
8.57%
Return On Invested Capital:
6.83%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Income Statement | ||||||
| Revenue | $3.5B | $3.5B | $2.4B | $906.2M | $1.1B | |
| Gross Profit | -- | -- | -- | $691.1M | $893.5M | |
| Operating Income | -- | -- | -- | $203.7M | $276.9M | |
| EBITDA | -- | -- | -- | $197.6M | $1.3B | |
| Diluted EPS | -- | -- | -- | $0.05 | $1.06 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.7B | $3.8B | $3.7B | $3.5B | -- | |
| Total Assets | $8.7B | $9.7B | $9B | $9.2B | -- | |
| Current Liabilities | $1.8B | $2.4B | $3.7B | $3B | -- | |
| Total Liabilities | $3.9B | $3.9B | $4B | $3.4B | -- | |
| Total Equity | $4.8B | $5.8B | $5B | $5.8B | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | $405.3M | $219.4M | $361.5M | |
| Cash From Investing | -- | -- | -- | -$216.3M | -$627.7M | |
| Cash From Financing | -- | -- | -- | $720.7M | -$117.9M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
SBHMY
Sector
Market Cap
$16.3B
$27.9M
Price % of 52-Week High
90.38%
51.04%
Dividend Yield
1.26%
0%
Shareholder Yield
3.11%
-1.49%
1-Year Price Total Return
118.6%
-16.66%
Beta (5-Year)
0.555
0.516
Dividend yield:
1.26%
Annualized payout:
$0.15
Payout ratio:
-27.49%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$18.22
200-day SMA
Buy
Level
$14.81
Bollinger Bands (100)
Sell
Level
18.7 - 20.1
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$18.40
Relative Strength Index (RSI14)
Sell
Level
1.32
ADX Line
Neutral
Level
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$19.08
MACD (12, 26)
Buy
Level
3.43
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
--
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8825)
Buy
CA Score
(Annual)
Level (0.0701)
Buy
Beneish M-Score
(Annual)
Level (-2.5113)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-2.0107)
Buy
Piotroski F Score
(Annual)
Level (9)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Investment, Modernised Chinese Medicines and Chemical Medicines; and Others. The Investment segment offers long-term investments. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long-term investments. The Other segment includes a research and development sector, which provides services to third parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse Cheung Ling Cheng and on February 2, 2000, and is headquartered in Hong Kong.
Stock Forecast FAQ
In the current month, SBHMY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SBHMY average analyst price target in the past 3 months is --.
-
Where Will Sino Biopharmaceutical Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sino Biopharmaceutical Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Sino Biopharmaceutical Ltd.?
Analysts are divided on their view about Sino Biopharmaceutical Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sino Biopharmaceutical Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is Sino Biopharmaceutical Ltd.'s Price Target?
The price target for Sino Biopharmaceutical Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SBHMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sino Biopharmaceutical Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SBHMY?
You can purchase shares of Sino Biopharmaceutical Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sino Biopharmaceutical Ltd. shares.
-
What Is The Sino Biopharmaceutical Ltd. Share Price Today?
Sino Biopharmaceutical Ltd. was last trading at $18.22 per share. This represents the most recent stock quote for Sino Biopharmaceutical Ltd.. Yesterday, Sino Biopharmaceutical Ltd. closed at $18.22 per share.
-
How To Buy Sino Biopharmaceutical Ltd. Stock Online?
In order to purchase Sino Biopharmaceutical Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SBHMY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SBHMY
Sector
P/E ratio
31.84x
23.85x
PEG ratio
0.33x
-0.01x
P/B ratio
4.29x
1.81x
Price / LTM sales
3.87x
1.58x
Growth Metrics
SBHMY
Sector
Revenue growth
--
4.62%
Earnings growth
--
10.7%
Revenue (5-year growth)
2.72%
6.5%
Earnings forecast
--
-$0.21
Profitability
SBHMY
Sector
Profitability FY 2024
$3.3B
$3.6M
Return on invested capital
6.83%
-31.87%
Return on assets
5.38%
-28.18%
Return on equity
8.57%
-37.63%
Earnings Date
Last Earnings Date
Aug
18
Next Earnings Date
Mar
19
Estimated Next Earnings Date
Nov
17
Balance Sheet
SBHMY
Sector
Total cash
$2B
$26.4M
Short term investments
$718.9M
$25.7M
Total assets
$9B
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 2.59% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.03% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
